Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 560,936 shares of the biopharmaceutical company's stock after selling 45,294 shares during the quarter. Mackenzie Financial Corp's holdings in Gilead Sciences were worth $51,814,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Redwood Financial Network Corp increased its stake in Gilead Sciences by 4.0% in the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after purchasing an additional 98 shares during the period. Nicolet Advisory Services LLC increased its stake in Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after purchasing an additional 100 shares during the period. Berkshire Bank increased its stake in Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 111 shares during the period. CFO4Life Group LLC increased its stake in Gilead Sciences by 2.7% in the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock worth $394,000 after purchasing an additional 112 shares during the period. Finally, Howe & Rusling Inc. increased its stake in Gilead Sciences by 2.5% in the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock worth $435,000 after purchasing an additional 115 shares during the period. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total value of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares of the company's stock, valued at $16,537,578.68. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,929 shares of company stock valued at $5,644,780 over the last quarter. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Piper Sandler increased their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, Oppenheimer dropped their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded down $1.16 on Friday, reaching $109.95. 2,025,043 shares of the stock were exchanged, compared to its average volume of 8,826,071. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The firm has a market capitalization of $136.77 billion, a price-to-earnings ratio of 297.16, a PEG ratio of 0.71 and a beta of 0.26. The business has a 50 day moving average price of $105.45 and a two-hundred day moving average price of $100.67.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the company posted ($1.32) earnings per share. The company's revenue was down .3% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.